Treatment Of Dementias

This book provides an overall introduction to the medical management of dementia with chapters dedicated to specific topics such as pain, epilepsy, vascular risk factors in dementia and review of medication, which are often not addressed in books on the subject, and thereby filling a gap in the field. Chapters are supplemented with cases to highlight key concepts and treatment approaches, and to provide the reader with the possibility to reflect on management options and the readers ́ own current practice. This book is aimed at clinicians of different specialties (mainly neurology, psychiatry, geriatric medicine and general practice/family medicine) who manage patients with dementia on a regular basis, and thus provides useful guidance to be used in the clinic.

Senile dementia is one of the major health problems confronting mankind in this century. To some extent the problem has, of course, always existed. The condition was sufficiently troubling to classical philosophers and jurists to have apparently provoked comments by Solon in approximately 500 B. C. and Plato in the fourth century B. C. (Plutarch 1967 translation; Plato 1921 translation). Medical recognition can be traced at least as far back as the second century A. D. (Adams 1861). However, several factors have converged in this century to extend the absolute dimensions of the problem of senile dementia and to increase societal, medical, and scientific recogni tion of the magnitude of the condition. Perhaps the most important factor relating to the present importance of senile dementia is demographic. Although the human population has been increasing since the mid-eighteenth century, it has only been since the advent of the twentieth century that a decrease in mortality has been noted for those over the age of 45 (McKeown 1976). Consequently, the absolute number of aged persons and the proportion of increasingly aged persons in the populations of the world's industrial nations have been steadily increasing. For example, in the United States, 4% ofthe population was over the age of 65 in 1900. In the 1970 census, this proportion had grown to 10%.

Treatments for age-related dementia and the growing reliance on pharmaceuticals to alleviate its worst symptoms raise a number of questions about attitudes toward aging and cognition, the relationship between growing older and getting sick, and the conflicting interests of patients, caregivers, physicians, scientists, and business. This volume aims to foster a constructive debate about the future of dementia treatment by providing multiple perspectives on these tangled issues. The first section examines how the concepts of dementia have expanded to encompass a broad range of symptoms and the implications of this evolution on the development of pharmaceutical treatments. The second section explores the use and effectiveness of drug treatments for dementia through the perspectives of a clinician, a researcher, and a layperson. In the third section, the contributors probe how culture, language, and values affect the overlapping worlds of pharmacology, drug marketing, and dementia treatment. A final section elucidates the thorny ethical and policy concerns surrounding the often-conflicting hopes for dementia medications. Featuring contributions from noted clinicians, researchers, and scholars from a broad range of disciplines, this multidisciplinary dialogue addresses central questions about the history and future of drug treatment for dementia and makes clear why there are no simple answers. Professionals and students involved in gerontology, psychiatry, and bioethics will find the discussion both enlightening and practical.

As the largest generation in U.S. history - the population born in the two decades immediately following World War II - enters the age of risk for cognitive impairment, growing numbers of people will experience dementia (including Alzheimer's disease and related dementias). By one estimate, nearly 14 million people in the United States will be living with dementia by 2060. Like other hardships, the experience of living with dementia can bring unexpected moments of intimacy, growth, and compassion, but these diseases also affect people's capacity to work and carry out other activities and alter their relationships with loved ones, friends, and coworkers. Those who live with and care for individuals experiencing these diseases face challenges that include physical and emotional stress, difficult changes and losses in their relationships with life partners, loss of income, and interrupted connections to other activities and friends. From a societal perspective, these diseases place substantial demands on communities and on the institutions and government entities that support people living with dementia and their families, including the health care system, the providers of direct care, and others. Nevertheless, research in the social and behavioral sciences points to possibilities for preventing or slowing the development of dementia and for substantially reducing its social and economic impacts. At the request of the National Institute on Aging of the U.S. Department of Health and Human Services, Reducing the Impact of Dementia in America assesses the contributions of research in the social and behavioral sciences and identifies a research agenda for the coming decade. This report offers a blueprint for the next decade of behavioral and social science research to reduce the negative impact of dementia for America's diverse population. Reducing the Impact of Dementia in America calls for research that addresses the causes and solutions for disparities in both developing dementia and receiving adequate treatment and support. It calls for research that sets goals meaningful not just for scientists but for people living with dementia and those who support them as well. By 2030, an estimated 8.5 million Americans will have Alzheimer's disease and many more will have other forms of dementia. Through identifying priorities social and behavioral science research and recommending ways in which they can be pursued in a coordinated fashion, Reducing the Impact of Dementia in America will help produce research that improves the lives of all those affected by dementia.

New edition, completely rewritten, with new chapters on endovascular surgery and mitochrondrial and ion channel disorders.

Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.

Now presented in full color, this updated edition of Memory Loss, Alzheimer's Disease, and Dementia is designed as a practical guide for clinicians that delivers the latest treatment approaches and research findings for dementia and related illnesses. Drs. Budson and Solomon — both key leaders in the field — cover the essentials of physical and cognitive examinations and laboratory and imaging studies, giving you the tools you need to consistently make accurate diagnoses in this rapidly growing area. Access in-depth coverage of clinically useful diagnostic tests and the latest treatment approaches. Detailed case studies facilitate the management of both common and uncommon conditions. Comprehensive coverage of hot topics such as chronic traumatic encephalopathy, in addition to new criteria on vascular dementia and vascular cognitive impairment. Includes new National Institute on Aging–Alzheimer's Association and DSM-5 criteria for Alzheimer’s Disease and Mild Cognitive Impairment. Learn how to use new diagnostic tests, such as the amyloid imaging scans florbetapir (Amyvid), flutemetamol (Vizamyl), and florbetaben (Neuraceq), which can display amyloid plaques in the living brains of patients. Updated case studies, many complete with videos illustrating common tests, clinical signs, and diagnostic features, are now incorporated into the main text as clinical vignettes for all major disorders. Brand-new chapters on how to approach the differential diagnosis and on primary progressive aphasia. Expert Consult eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, references, and videos from the book on a variety of devices.